Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Sep 28

PMID 37760447

Authors

Riet Hilhorst

Adrienne van den Berg

Piet Boender

Tom van Wezel

Tim Kievits

Rik de Wijn

Rob Ruijtenbeek

Willem E Corver

Hans Morreau

Affiliations

Soon will be listed here.

Abstract

Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery followed by radioactive iodide therapy. However, a small subset of patients shows recurrence due to a loss of iodide transport, a phenotype frequently associated with BRAF V600E mutations. In theory, this should enable the use of existing targeted therapies specifically designed for BRAF V600E mutations. However, in practice, generic or specific drugs aimed at molecular targets identified by next generation sequencing (NGS) are not always beneficial. Detailed kinase profiling may provide additional information to help improve therapy success rates. In this study, we therefore investigated whether serine/threonine kinase (STK) activity profiling can accurately classify benign thyroid lesions and NMTC. We also determined whether dabrafenib (BRAF V600E-specific inhibitor), as well as sorafenib and regorafenib (RAF inhibitors), can differentiate BRAF V600E from non-BRAF V600E thyroid tumors. Using 21 benign and 34 malignant frozen thyroid tumor samples, we analyzed serine/threonine kinase activity using PamChippeptide microarrays. An STK kinase activity classifier successfully differentiated malignant (26/34; 76%) from benign tumors (16/21; 76%). Of the kinases analyzed, PKC (theta) and PKD1 in particular, showed differential activity in benign and malignant tumors, while oncocytic neoplasia or Graves' disease contributed to erroneous classifications. Ex vivo BRAF V600E-specific dabrafenib kinase inhibition identified 6/92 analyzed peptides, capable of differentiating BRAF V600E-mutant from non-BRAF V600E papillary thyroid cancers (PTCs), an effect not seen with the generic inhibitors sorafenib and regorafenib. In conclusion, STK activity profiling differentiates benign from malignant thyroid tumors and generates unbiased hypotheses regarding differentially active kinases. This approach can serve as a model to select novel kinase inhibitors based on tissue analysis of recurrent thyroid and other cancers.

References

Huo K, Notsuda H, Fang Z, Liu N, Gebregiworgis T, Li Q . Lung Cancer Driven by BRAF Mutation Is Targetable by EGFR Kinase Inhibitors. J Thorac Oncol. 2021; 17(2):277-288. DOI: 10.1016/j.jtho.2021.09.008. View

Sibinga Mulder B, Mieog J, Handgraaf H, Sarasqueta A, Vasen H, Potjer T . Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. J Clin Pathol. 2016; 70(2):174-178. DOI: 10.1136/jclinpath-2016-203928. View

Rothenberg S, McFadden D, Palmer E, Daniels G, Wirth L . Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015; 21(5):1028-35. DOI: 10.1158/1078-0432.CCR-14-2915. View

Brose M, Cabanillas M, Cohen E, Wirth L, Riehl T, Yue H . Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(9):1272-82. PMC: 5532535. DOI: 10.1016/S1470-2045(16)30166-8. View

Corver W, Ruano D, Weijers K, Hartog W, van Nieuwenhuizen M, de Miranda N . Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma. PLoS One. 2012; 7(6):e38287. PMC: 3365880. DOI: 10.1371/journal.pone.0038287. View

Tchekmedyian V, Dunn L, Sherman E, Baxi S, Grewal R, Larson S . Enhancing Radioiodine Incorporation in -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid. 2022; 32(3):273-282. PMC: 9206492. DOI: 10.1089/thy.2021.0565. View

SALABE G . Pathogenesis of thyroid nodules: histological classification?. Biomed Pharmacother. 2001; 55(1):39-53. DOI: 10.1016/s0753-3322(00)00010-x. View

Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384(9940):319-28. PMC: 4366116. DOI: 10.1016/S0140-6736(14)60421-9. View

Iravani A, Solomon B, Pattison D, Jackson P, Kumar A, Kong G . Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid. 2019; 29(11):1634-1645. DOI: 10.1089/thy.2019.0143. View

10.

Chirumamilla C, Fazil M, Perez-Novo C, Rangarajan S, de Wijn R, Ramireddy P . Profiling Activity of Cellular Kinases in Migrating T-Cells. Methods Mol Biol. 2019; 1930:99-113. DOI: 10.1007/978-1-4939-9036-8_13. View

11.

Bible K, Ryder M . Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016; 13(7):403-16. DOI: 10.1038/nrclinonc.2016.19. View

12.

Falchook G, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack S . BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2014; 25(1):71-7. PMC: 4291160. DOI: 10.1089/thy.2014.0123. View

13.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877-88. DOI: 10.1056/NEJMoa1406037. View

14.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

15.

Corver W, Middeldorp A, Ter Haar N, Jordanova E, van Puijenbroek M, van Eijk R . Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. Cancer Res. 2008; 68(24):10333-40. DOI: 10.1158/0008-5472.CAN-08-2665. View

16.

Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L . Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers (Basel). 2020; 12(2). PMC: 7072684. DOI: 10.3390/cancers12020512. View

17.

Kari S, Vasko V, Priya S, Kirschner L . PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer. Front Endocrinol (Lausanne). 2019; 10:769. PMC: 6874117. DOI: 10.3389/fendo.2019.00769. View

18.

Pearson W . Selecting the Right Similarity-Scoring Matrix. Curr Protoc Bioinformatics. 2014; 43:3.5.1-3.5.9. PMC: 3848038. DOI: 10.1002/0471250953.bi0305s43. View

19.

Arni S, Le T, de Wijn R, Garcia-Villegas R, Dankers M, Weder W . multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma. Oncotarget. 2017; 8(40):68599-68613. PMC: 5620281. DOI: 10.18632/oncotarget.19803. View

20.

Saavedra A, Tsygankova O, Prendergast G, Dworet J, Cheng G, Meinkoth J . Role of cAMP, PKA and Rap1A in thyroid follicular cell survival. Oncogene. 2002; 21(5):778-88. DOI: 10.1038/sj.onc.1205123. View